O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125

has been cited by the following article:

• TITLE: Cholangiocarcinoma in Patients with Crohn’s Disease

  AUTHORS: Tarek Debs, Isabella Reccia, Imad El-Hajj, Ziad El-Rassi

  KEYWORDS: Cholangiocarcinoma, Crohn’s, Inflammatory Bowel Disease, Infliximab

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.1, December 26, 2014

  ABSTRACT: Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn’s disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues.